文献速递儿科与产科急症重症综合管理与镇静镇痛

体外循环一氧化氮对先天性心脏病手术幼儿无呼吸机日的影响:NITRIC随机临床试验

Effect of Nitric Oxide via Cardiopulmonary Bypass on Ventilator-Free Days in Young Children Undergoing Congenital Heart Disease Surgery: The NITRIC Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01
一句话结论在2岁以下先天性心脏病手术患儿中,体外循环氧合器给一氧化氮未显著改善无呼吸机日,作者认为该发现不支持术中经氧合器给一氧化氮。

NITRIC试验为双盲、多中心随机临床试验,在澳大利亚、新西兰和荷兰6个儿童心脏手术中心纳入1371例2岁以下先天性心脏病手术患儿,随机接受体外循环氧合器20 ppm一氧化氮(n=679)或标准体外循环(n=685)。主要终点无呼吸机日中位数一氧化氮组26.6天 vs 标准组26.4天,绝对差-0.01天(95%CI -0.25至0.22;P=0.92),无显著差异。低心输出量综合征、体外生命支持或死亡的复合终点两组分别为22.5% vs 20.9%,校正OR 1.12(95%CI 0.85至1.47)。作者结论认为这些发现不支持心脏手术期间经体外循环氧合器给一氧化氮。

要点

  • 2岁以下先天性心脏病手术患儿,体外循环氧合器给20 ppm一氧化氮 vs 标准体外循环,无呼吸机日中位数26.6天 vs 26.4天,绝对差-0.01天(95%CI -0.25至0.22;P=0.92)。
  • 复合终点(48小时内低心输出量综合征、48小时内需体外支持或28天内死亡)一氧化氮组22.5% vs 标准组20.9%,校正OR 1.12(95%CI 0.85至1.47)。
  • 其他次要终点(ICU住院时间、住院时间、术后肌钙蛋白水平)两组无显著差异。
  • 作者结论:体外循环给一氧化氮未显著影响无呼吸机日,这些发现不支持心脏手术期间经体外循环氧合器给一氧化氮。

适用人群与场景

  • 2岁以下接受先天性心脏病手术的患儿,来自澳大利亚、新西兰和荷兰6个儿童心脏手术中心。
  • 随机分组1371例,平均(SD)年龄21.2(23.5)周,女孩587例(42.8%);1364例(99.5%)完成试验。

处置流程与药物剂量

  • 干预组体外循环氧合器给一氧化氮20 ppm(n=679);对照组标准体外循环不给一氧化氮(n=685)。
  • 主要终点为从体外循环开始至第28天的无呼吸机日(存活且脱离机械通气的天数)。

研究设计与关键结果

  • 双盲、多中心随机临床试验,6个中心,1371例2岁以下先天性心脏病手术患儿,随机接受体外循环氧合器20 ppm一氧化氮(n=679)或标准体外循环(n=685)。
  • 主要终点无呼吸机日中位数一氧化氮组26.6天(IQR 24.4至27.4) vs 标准组26.4天(IQR 24.0至27.2),绝对差-0.01天(95%CI -0.25至0.22;P=0.92),无显著差异。
  • 复合终点(48小时内低心输出量综合征、48小时内需体外生命支持或28天内死亡)一氧化氮组22.5% vs 标准组20.9%,校正OR 1.12(95%CI 0.85至1.47)。
  • 其他次要终点(ICU住院时间、住院时间、术后肌钙蛋白水平)两组无显著差异。

证据类型、等级与局限

  • 证据类型:双盲、多中心随机临床试验。
  • 试验注册号:anzctr.org.au ACTRN12617000821392。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在2岁以下接受体外循环先天性心脏病手术的患儿中,经体外循环给一氧化氮未显著影响无呼吸机日,这些发现不支持心脏手术期间经体外循环氧合器给一氧化氮。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: In children undergoing heart surgery, nitric oxide administered into the gas flow of the cardiopulmonary bypass oxygenator may reduce postoperative low cardiac output syndrome, leading to improved recovery and shorter duration of respiratory support. It remains uncertain whether nitric oxide administered into the cardiopulmonary bypass oxygenator improves ventilator-free days (days alive and free from mechanical ventilation).

OBJECTIVE: To determine the effect of nitric oxide applied into the cardiopulmonary bypass oxygenator vs standard care on ventilator-free days in children undergoing surgery for congenital heart disease.

DESIGN, SETTING, AND PARTICIPANTS: Double-blind, multicenter, randomized clinical trial in 6 pediatric cardiac surgical centers in Australia, New Zealand, and the Netherlands. A total of 1371 children younger than 2 years undergoing congenital heart surgery were randomized between July 2017 and April 2021, with 28-day follow-up of the last participant completed on May 24, 2021.

INTERVENTIONS: Patients were assigned to receive nitric oxide at 20 ppm delivered into the cardiopulmonary bypass oxygenator (n = 679) or standard care cardiopulmonary bypass without nitric oxide (n = 685).

MAIN OUTCOMES AND MEASURES: The primary end point was the number of ventilator-free days from commencement of bypass until day 28. There were 4 secondary end points including a composite of low cardiac output syndrome, extracorporeal life support, or death; length of stay in the intensive care unit; length of stay in the hospital; and postoperative troponin levels.

RESULTS: Among 1371 patients who were randomized (mean [SD] age, 21.2 [23.5] weeks; 587 girls [42.8%]), 1364 (99.5%) completed the trial. The number of ventilator-free days did not differ significantly between the nitric oxide and standard care groups, with a median of 26.6 days (IQR, 24.4 to 27.4) vs 26.4 days (IQR, 24.0 to 27.2), respectively, for an absolute difference of -0.01 days (95% CI, -0.25 to 0.22; P = .92). A total of 22.5% of the nitric oxide group and 20.9% of the standard care group developed low cardiac output syndrome within 48 hours, needed extracorporeal support within 48 hours, or died by day 28, for an adjusted odds ratio of 1.12 (95% CI, 0.85 to 1.47). Other secondary outcomes were not significantly different between the groups.

CONCLUSIONS AND RELEVANCE: In children younger than 2 years undergoing cardiopulmonary bypass surgery for congenital heart disease, the use of nitric oxide via cardiopulmonary bypass did not significantly affect the number of ventilator-free days. These findings do not support the use of nitric oxide delivered into the cardiopulmonary bypass oxygenator during heart surgery.

TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12617000821392.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Schlapbach LJ, Gibbons KS, Horton SB, et al. Effect of Nitric Oxide via Cardiopulmonary Bypass on Ventilator-Free Days in Young Children Undergoing Congenital Heart Disease Surgery: The NITRIC Randomized Clinical Trial. JAMA. 2022. PMID: 35759691. doi:10.1001/jama.2022.9376

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。